03:32 PM EST, 12/10/2024 (MT Newswires) -- Jazz Pharmaceuticals' ( JAZZ ) investor event on Wednesday is expected to set the stage for commercial

launch possibly next year of its biliary tract cancer treatment Ziihera, RBC Capital Markets said in a note.

The US Food and Drug Administration's accelerated approval of Ziihera "brings Jazz a step closer towards new revenue stream" and "marks a de-risking event for Ziihera's development in earlier lines of [biliary tract cancer], as well as additional HER2+ indications such as [gastroesophageal adenocarcinomas and breast cancer]," RBC said in the note sent Tuesday.

RBC projects about $930 million in peak sales in 2033 for Ziihera.

"Longer term, Ziihera could serve as a growth lever to break Jazz out of the current trading range," it said.

RBC is maintaining its outperform rating on the stock and $179 price target.

Price: 121.12, Change: +0.31, Percent Change: +0.26